Aligos Therapeutics, Inc.
ALGS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $101,621 | $74,632 | $69,370 | $250,277 |
| - Cash | $41,946 | $18,771 | $73,763 | $36,997 |
| + Debt | $6,065 | $6,878 | $7,874 | $8,375 |
| Enterprise Value | $65,740 | $62,739 | $3,481 | $221,655 |
| Revenue | $741 | $965 | $311 | $629 |
| % Growth | -23.2% | 210.3% | -50.6% | – |
| Gross Profit | $741 | $706 | $311 | $629 |
| % Margin | 100% | 73.2% | 100% | 100% |
| EBITDA | -$30,783 | -$15,419 | -$18,733 | -$19,892 |
| % Margin | -4,154.3% | -1,597.8% | -6,023.5% | -3,162.5% |
| Net Income | -$31,537 | -$15,863 | $43,088 | -$82,150 |
| % Margin | -4,256% | -1,643.8% | 13,854.7% | -13,060.4% |
| EPS Diluted | -3.04 | -1.53 | -2.11 | -13.08 |
| % Growth | -98.7% | 27.5% | 83.9% | – |
| Operating Cash Flow | -$24,345 | -$15,504 | -$20,909 | -$18,403 |
| Capital Expenditures | -$193 | -$109 | -$43 | -$28 |
| Free Cash Flow | -$24,538 | -$15,613 | -$20,952 | -$18,431 |